CN101506196B - 能够抑制ubc13-uev相互作用的化合物、药物组合物及治疗用途 - Google Patents

能够抑制ubc13-uev相互作用的化合物、药物组合物及治疗用途 Download PDF

Info

Publication number
CN101506196B
CN101506196B CN2007800313305A CN200780031330A CN101506196B CN 101506196 B CN101506196 B CN 101506196B CN 2007800313305 A CN2007800313305 A CN 2007800313305A CN 200780031330 A CN200780031330 A CN 200780031330A CN 101506196 B CN101506196 B CN 101506196B
Authority
CN
China
Prior art keywords
compound
ubc13
dimethylformamide
ethyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800313305A
Other languages
English (en)
Chinese (zh)
Other versions
CN101506196A (zh
Inventor
蒂莫西·汤姆森奥卡图
约翰娜·舍佩尔西格蒙德
安赫尔·梅塞盖尔佩普克
安赫尔·拉米雷斯奥蒂斯
格洛利亚·圣克里门斯佩里茨德罗萨斯
伊莎贝尔·麦斯普麦斯普
亚历杭德拉·莫雷费尔南德斯
多明戈·冈萨雷斯鲁伊斯
安东尼奥·莫雷亚莱德莱昂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Publication of CN101506196A publication Critical patent/CN101506196A/zh
Application granted granted Critical
Publication of CN101506196B publication Critical patent/CN101506196B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2007800313305A 2006-07-20 2007-03-07 能够抑制ubc13-uev相互作用的化合物、药物组合物及治疗用途 Expired - Fee Related CN101506196B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200601933A ES2293834B1 (es) 2006-07-20 2006-07-20 Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.
ESP200601933 2006-07-20
PCT/ES2007/000120 WO2008009758A1 (es) 2006-07-20 2007-03-07 Compuestos con actividad inhibidora de las interacciones ubc13-uev, composiciones farmacéuticas y aplicaciones terapéuticas

Publications (2)

Publication Number Publication Date
CN101506196A CN101506196A (zh) 2009-08-12
CN101506196B true CN101506196B (zh) 2013-11-20

Family

ID=38956569

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800313305A Expired - Fee Related CN101506196B (zh) 2006-07-20 2007-03-07 能够抑制ubc13-uev相互作用的化合物、药物组合物及治疗用途

Country Status (9)

Country Link
US (2) US8252786B2 (https=)
EP (1) EP2045251B1 (https=)
JP (1) JP5203363B2 (https=)
CN (1) CN101506196B (https=)
AU (1) AU2007275073B2 (https=)
CA (1) CA2658327C (https=)
ES (1) ES2293834B1 (https=)
MX (1) MX2009000672A (https=)
WO (1) WO2008009758A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138380A2 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
EP3269395A1 (en) 2008-11-07 2018-01-17 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US9040701B2 (en) 2009-07-30 2015-05-26 Laboratorios Salvat, S.A. Apaf-1 inhibitor compounds
EP3318248B1 (en) 2009-12-01 2019-04-10 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US20130345231A1 (en) * 2011-03-23 2013-12-26 Indiana University Research And Technology Corporation Anticancer therapeutic agents
EP2691443B1 (en) 2011-03-28 2021-02-17 Massachusetts Institute of Technology Conjugated lipomers and uses thereof
RU2013154295A (ru) 2011-06-08 2015-07-20 Шир Хьюман Дженетик Терапис, Инк. КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК
PE20181541A1 (es) * 2011-10-27 2018-09-26 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
US20130236504A1 (en) * 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
JP6586075B2 (ja) 2013-03-14 2019-10-02 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの精製方法
RS57739B1 (sr) 2013-03-14 2018-12-31 Translate Bio Inc Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
CN106413811A (zh) 2013-10-22 2017-02-15 夏尔人类遗传性治疗公司 精氨基琥珀酸合成酶缺乏症的mrna疗法
JP6506749B2 (ja) 2013-10-22 2019-04-24 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド フェニルケトン尿症のためのｍＲＮＡ療法
ES3032935T3 (en) 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
JP6295767B2 (ja) 2014-03-25 2018-03-20 富士通株式会社 スイッチ装置、情報処理システムおよびスイッチ装置の制御方法
US9850269B2 (en) 2014-04-25 2017-12-26 Translate Bio, Inc. Methods for purification of messenger RNA
JP6557722B2 (ja) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための生分解性脂質
KR102559979B1 (ko) 2014-06-24 2023-07-25 샤이어 휴먼 지네틱 테라피즈 인크. 핵산의 전달용 입체화학적으로 풍부한 조성물
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016205691A1 (en) 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
EA201991747A1 (ru) 2017-02-27 2020-06-04 Транслейт Био, Инк. НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
MX2019013752A (es) 2017-05-16 2020-07-20 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
KR102950141B1 (ko) 2018-08-24 2026-04-07 트랜슬레이트 바이오 인코포레이티드 전령 rna의 정제 방법
WO2020106946A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
EP4516300A3 (en) * 2019-06-14 2025-08-06 Children's Hospital Medical Center Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n
EP4031662A1 (en) 2019-09-20 2022-07-27 Translate Bio, Inc. Mrna encoding engineered cftr
KR20220017075A (ko) 2020-08-04 2022-02-11 삼성전자주식회사 홈 화면을 복원하는 방법 및 이를 적용한 전자 장치
WO2023225277A1 (en) * 2022-05-19 2023-11-23 Ohio State Innovation Foundation Peptidyl flavor modifiers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011750A2 (en) * 2000-08-08 2002-02-14 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway
WO2002028885A1 (es) * 2000-10-06 2002-04-11 Diverdrugs, S.L. Trímeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotóxicas, y composiciones que los contienen
US20030069189A1 (en) * 1997-02-15 2003-04-10 Millennium Pharmaceuticals, Inc. Treatment of infarcts

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW200538149A (en) 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
ES2296484B1 (es) * 2005-11-23 2009-04-01 Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (90%) Composicion farmaceutica para inhibir la apoptosis.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069189A1 (en) * 1997-02-15 2003-04-10 Millennium Pharmaceuticals, Inc. Treatment of infarcts
WO2002011750A2 (en) * 2000-08-08 2002-02-14 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway
WO2002028885A1 (es) * 2000-10-06 2002-04-11 Diverdrugs, S.L. Trímeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotóxicas, y composiciones que los contienen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Isabel Masip et al.,.Design and synthesis of an optimized positional scanning library of peptoids: identification of novel multidrug resistance reversal agents.《Bioorganic & Medicinal Chemistry》.2005,第13卷第1923-1929页. *
Isabel Masip et al.,.Synthesis of a Library of 3-Oxopiperazinium and Perhydro-3-oxo-1,4-diazepinium Derivatives and Identification of Bioactive Compounds.《Journal of Combinatorial Chemistry》.2003,第6卷(第1期),第135-141页. *

Also Published As

Publication number Publication date
EP2045251A4 (en) 2010-12-01
CA2658327A1 (en) 2008-01-24
AU2007275073A1 (en) 2008-01-24
MX2009000672A (es) 2009-02-04
CA2658327C (en) 2013-12-03
ES2293834B1 (es) 2009-02-16
CN101506196A (zh) 2009-08-12
EP2045251A1 (en) 2009-04-08
JP2009544600A (ja) 2009-12-17
AU2007275073B2 (en) 2012-06-07
EP2045251B1 (en) 2015-11-18
US20130237529A1 (en) 2013-09-12
US8252786B2 (en) 2012-08-28
ES2293834A1 (es) 2008-03-16
WO2008009758A1 (es) 2008-01-24
US20110160189A1 (en) 2011-06-30
JP5203363B2 (ja) 2013-06-05
US8785430B2 (en) 2014-07-22

Similar Documents

Publication Publication Date Title
CN101506196B (zh) 能够抑制ubc13-uev相互作用的化合物、药物组合物及治疗用途
JP6970802B2 (ja) 二官能性分子によって標的化タンパク質分解を誘導する方法
US20220387602A1 (en) Bifunctional degraders and their methods of use
CN108314677B (zh) 一种ezh2抑制剂及其用途
AU2004231514B2 (en) Reverse-turn mimetics and method relating thereto
KR101257824B1 (ko) 리버스-턴 유사체 및 이와 관련된 방법
AU2015222805B2 (en) Treatment of conditions associated with hyperinsulinaemia
EP3491353A1 (en) Small molecule activators of parkin enzyme function
IL229387A (en) Spiro-oxindole antagonists of mdm2
KR20180019083A (ko) (6Ｓ,9ａＳ)-Ｎ-벤질-6-[(4-하이드록시페닐)메틸]-4,7-디옥소-8-(｛6-[3-(피페라진-1-일)아제티딘-1-일]피리딘-2-일｝메틸)-2-(프로프-2-엔-1-일)-옥타하이드로-1Ｈ-피라지노[2,1-ｃ][1,2,4]트리아진-1-카복사마이드 화합물의 결정
US20070043052A1 (en) Reverse-turn mimetics and method relating thereto
CA3065163A1 (en) Antibiotic resistance breakers
CN106536524B (zh) 用于在增殖性疾病的治疗中使用的[1,2,4]三唑并[4,3-b]哒嗪
US20220274997A1 (en) Pim kinase inhibitor compositions and uses thereof
ES2976567T3 (es) Formas cristalinas de (1-pirimidin-2-il-ciclopropil)-amida del ácido (3S,4S)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3-carbonil]-amino}-piperidin-3-carboxílico
US20230212122A1 (en) Mitochondrial targeting compounds for the treatment of associated diseases
Simonov et al. Synthesis of 4-substituted 3-[3-(dialkylaminomethyl) indol-1-yl] maleimides and study of their ability to inhibit protein kinase C-α, prevent development of multiple drug resistance of tumor cells and cytotoxicity
Al-Warhi et al. Piperidine-based small molecules as dual-stage antileishmanial agents targeting parasite folate pathway
Ayala Identification of a privileged scaffold to accelerate DUB drug discovery
BR122024019068A2 (pt) Método de preparação de forma cristalina de (s) -7- (1- acriloilpiperidin- 4-il) -2- (4-fenoxifenil) -4,5,6,7-tetra-hidropirazol [1,5-a] pirimidina- 3-carboxamida
BR122024019067A2 (pt) Forma cristalina de (s) -7- (1-acriloilpiperidin-4-il) -2- (4-fenoxifenil) -4,5,6,7-tetra-hidropirazol [1,5-a] pirimidina-3-carboxamida, sua preparação e seus usos

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131120

Termination date: 20160307